AbbVie Inc (NYSE:ABBV) – William Blair issued their FY2021 EPS estimates for shares of AbbVie in a research note issued on Wednesday, April 17th. William Blair analyst Y. Xu forecasts that the company will post earnings of $9.35 per share for the year.
Several other equities analysts have also recently issued reports on the company. Bank of America cut AbbVie from a “buy” rating to a “neutral” rating in a report on Thursday, January 3rd. Argus lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Standpoint Research began coverage on AbbVie in a research report on Wednesday, December 26th. They issued a “buy” rating on the stock. Credit Suisse Group set a $79.00 target price on AbbVie and gave the company a “hold” rating in a research report on Friday, January 25th. Finally, ValuEngine lowered AbbVie from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Six research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $94.48.
Shares of NYSE ABBV opened at $77.98 on Thursday. AbbVie has a one year low of $75.77 and a one year high of $107.25. The firm has a market capitalization of $119.53 billion, a P/E ratio of 9.86, a PEG ratio of 1.66 and a beta of 1.16.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 25th. The company reported $1.90 EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($0.02). The firm had revenue of $8.31 billion during the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a net margin of 17.36% and a negative return on equity of 439.07%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.48 earnings per share.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a $1.07 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $4.28 annualized dividend and a yield of 5.49%. AbbVie’s dividend payout ratio (DPR) is presently 54.11%.
In other news, EVP Azita Saleki-Gerhardt sold 15,797 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $79.03, for a total transaction of $1,248,436.91. Following the completion of the sale, the executive vice president now directly owns 93,312 shares in the company, valued at approximately $7,374,447.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Vice Chairman Laura J. Schumacher sold 25,000 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $80.00, for a total value of $2,000,000.00. Following the sale, the insider now owns 139,838 shares of the company’s stock, valued at $11,187,040. The disclosure for this sale can be found here. Insiders sold a total of 41,272 shares of company stock valued at $3,286,290 over the last 90 days. 0.08% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in AbbVie by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 118,762,307 shares of the company’s stock worth $11,232,540,000 after purchasing an additional 912,625 shares in the last quarter. Vanguard Group Inc increased its stake in shares of AbbVie by 0.8% in the third quarter. Vanguard Group Inc now owns 118,762,307 shares of the company’s stock valued at $11,232,540,000 after buying an additional 912,625 shares during the period. Capital International Investors increased its stake in shares of AbbVie by 266.4% in the third quarter. Capital International Investors now owns 27,594,648 shares of the company’s stock valued at $2,609,902,000 after buying an additional 20,063,435 shares during the period. Capital World Investors increased its stake in shares of AbbVie by 74.9% in the third quarter. Capital World Investors now owns 25,359,025 shares of the company’s stock valued at $2,398,457,000 after buying an additional 10,858,432 shares during the period. Finally, Northern Trust Corp increased its stake in shares of AbbVie by 1.1% in the fourth quarter. Northern Trust Corp now owns 21,029,665 shares of the company’s stock valued at $1,938,725,000 after buying an additional 227,408 shares during the period. Hedge funds and other institutional investors own 70.66% of the company’s stock.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.